Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2025-12-25 @ 11:46 PM
NCT ID: NCT03050294
Description: None
Frequency Threshold: 0
Time Frame: 2 weeks
Study: NCT03050294
Study Brief: Evaluating Treatment Resistant Dermatitis TaroIIR
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Control- Atopic Dermatitis Participants with atopic dermatitis will receive desoximetasone and no calls. Desoximetasone 0.25% spray: Desoximetasone 0.25% spray applied twice daily 0 None 0 6 0 6 View
Control- Psoriasis Participants with psoriasis will receive desoximetasone and no calls. Desoximetasone 0.25% spray: Desoximetasone 0.25% spray applied twice daily 0 None 0 6 0 6 View
Psoriasis Intervention Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication. Phone calls: Phone calls twice daily Desoximetasone 0.25% spray: Desoximetasone 0.25% spray applied twice daily 0 None 0 6 0 6 View
Atopic Dermatitis Intervention Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication. Phone calls: Phone calls twice daily Desoximetasone 0.25% spray: Desoximetasone 0.25% spray applied twice daily 0 None 0 6 0 6 View
Serious Events(If Any):
Other Events(If Any):